Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
– Received FDA Clearance of IND Application for DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss –
Related news for (DBTX)
- DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. – DBTX
- Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
- Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
- Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
- Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO